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TEN YEARS EXPERIENCE WITH JORGE LOBO’S DISEASE IN THE STATE OF ACRE, AMAZON 
REGION, BRAZIL 
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SUMMARY
Jorge Lobo’s disease is a cutaneous and subcutaneous mycosis that affects patients in the Amazon region. The number of patients 
is relatively small, but the real situation of the disease as public health problem is not known, because Jorge Lobo’s disease is not a 
notifiable disease. This study aims to report the clinical evolution in patients affected and to determine the prevalence and areas of 
occurrence of the disease. A retrospective study was carried out based on the analysis of the clinical records, which included a collection 
of photographs of patients in the Department of Sanitary Dermatology, in Rio Branco, and patients seen in the interior of the state. In 
a decade, in Rio Branco, 249 cases of the disease were reported, 30 were females and 219 males. Of these patients, 153 had localized 
lesions, 94 of them were on one ear, 55 had multifocal lesions and 41 had disseminated lesions. The average time between the onset 
of symptoms and diagnosis was 19 years. The average age at the time of diagnosis was 53 years, and ages ranged from 14 to 96 years.
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INTRODUCTION
Jorge Lobo’s disease, also known as lobomycosis and lacaziosis, was 
described for the first time in 1931 by Jorge Oliveira Lobo, physician 
and professor of Dermatology from the School of Medicine of Recife, 
PE13. The patient, a 52 years-old male, had worked as a rubber cutter 
in the Amazon and had skin lesions resembling keloid scars. Between 
1938 and 1962 there were 29 cases registered in Brazil, one in Costa 
Rica, two in Venezuela, and two in French Guiana11. BARUZZI et 
al.2,4 reported numerous cases among Caiabi Indians living in an area 
between the rivers Teles Pires and Tapajós, in the North of the state of 
Mato Grosso. Interestingly, when these Indians were transferred to the 
Xingu Indigenous National Park, no new case arose in the tribe. This may 
indicate there was no source of contamination in the Xingu National Park. 
Other indigenous tribes that inhabit the North of Mato Grosso State, in 
Brazil, do not have the disease. The high incidence among Caiabi Indians 
indicates that besides the risk factors, it is likely that there is a genetic 
susceptibility that predisposes to Jorge Lobo’s disease.
In Europe, one case was observed by SYMMERS31, the patient 
was an attendant who took care of a dolphin infected with the disease. 
BURNS et al.5 reported the first case in the United States in a man of 42 
years from Georgia, which referred to the appearance of lesions on the 
skin, after a trip to Venezuela where he had done rappelling in Angel 
Falls in Canaima. 
Some authors refer to constant increase in number of Jorge Lobo’s 
disease cases. SILVA & NEVES28 cited 252 cases in Brazil and 385 in 
the world. According to PRADINAUD & TALHARI21, the statistics in 
1996 was 418 cases worldwide. This remained unchanged until 1998, 
when the number of cases reported in Brazil was 2557. OPROMOLLA 
et al.17 estimated that 458 patients were diagnosed with the disease, of 
which 295 were in Brazil and 40 of these cases were in the state of Acre. 
Jorge Lobo’s disease is found, almost exclusively, in the tropical 
zone of the rainforest. The Brazilian Amazon valley has the climatic 
characteristics favoring the disease, tropical, hot and humid equatorial 
climate (Fig. 1). Until today, it is unclear which factors may act in the 
susceptibility and spread of the disease2. The transmission of Jorge 
Lobo’s disease is probably by contact of the infectious material with 
skin solutions of continuity. Evidence suggests the skin as portal of entry 
of the fungus by the fact that the lesions are located almost exclusively 
in skin tissue. 
The proven presence of dolphins with L. loboi indicates that the 
infective material must be present in seawater or freshwater. In 1971, 
MIGAKI et al.15 described the first case of the disease in dolphins, a 
specimen (Tursiops trucantus) caught on the West coast of Florida. A 
second case, also in Florida, was studied by WOODWARD35. DE VRIES 
& LAARMAN8 described a new case in a dolphin (Sotalia guianensis) 
caught in the estuary of the river Surinam. In 1970, another dolphin was 
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caught in the Bay of Biscay to the north of the Gulf of Biscay (Europe), 
with lesions of the disease, and was registered as the first case of the 
disease in dolphins caught in European waters31. Jules Sotos, coordinator 
of the museum of oceanography at the University of the Itajaí valley, in 
2007, reported the death of a dolphin, which ran aground on the central 
beach of the city Navegantes. The female dolphin had Jorge Lobo’s 
disease, and presented with the body and the palate covered with sores, 
caused by this fungi30. For 15 years the biologist Marcos de Oliveira 
Santos has carried out research on the life and routine of dolphins that 
live near the shores of São Paulo State and near the shores of Northern 
Paraná, and more precisely in Cananéia, Paranaguá. In 2006 and 2007 
he observed that these animals had marks on the skin. With the help of 
Marie-Francoise Van Bressen, a Dutch veterinary specialist, who works 
at the Center for Research of Cetaceans in Peru, identified the markings 
as Jorge Lobo’s disease. The study was based on more than one hundred 
photographs32.
Jorge Lobo’s disease affects mainly the subcutaneous tissues and 
skin, but the fungi can be present in regional lymph nodes20 and has 
been described in the testicle in an isolated case23. There are no reports 
of involvement of the general condition of the patients, except when 
there is extensive ulceration of the lesions with secondary infection25. 
When there are multiple large lesions, besides the deformity, the itching 
becomes unbearable34.
SILVA25 and SILVA & DE BRITO27 proposed a clinical classification 
based on the morphology of the lesions: infiltrative, keloid-like, 
in plaques, verruciform and ulcerated. According to BARUZZI & 
AZEVEDO1 and LACAZ et al.11 to facilitate surgical excision, lesions 
were classified according to their distribution: 1) isolated or localized 
forms and 2) disseminated forms. According to OPROMOLLA et 
al.17 the lesions can be classified as 1) isolated or localized forms, 2) 
disseminated forms and 3) multifocal forms (in one limb or section 
of the limb). In the chronic phase of the disease, it can be noted there 
is great polymorphism of the cutaneous lesions, with the presence of 
macules, papules, infiltrated plaques, nodules, often resembling keloids, 
gummy formation, besides the wart like lesions. The lesions in the lower 
limbs are often ulcerated11. 
The etiologic agent of this disease, L. loboi, appears abundantly 
in skin lesions as round yeast-like cells, measuring 6 to 12 μm in 
diameter, with a thick cell wall and cytoplasm with homogeneous or 
granular contents5,11. This fungus reproduces itself by simple budding, 
also presents catenulated forms with 3-6 cells together, forming a stem 
structure like in a rosary. Although the amount of fungi in parasitized 
tissue is large, many of the fungal cells are not viable11,19. 
There were many attempts to find a cure for Jorge Lobo’s disease 
but there have been few satisfactory results. The drugs and outcome of 
treatment schemes for the disease are demonstrated in Table 1.
The present study aimed to estimate the prevalence of Jorge Lobo’s 
disease in the patients registered in the Outpatient Clinic of the Service 
of Dermatology of the Emergency Hospital in Rio Branco, in the state 
of Acre, from 1998 to 2008, and to better understand the factors that 
may relate to the infection of patients and risk factors involved in 
its transmission. We intend to analyze the time between the onset of 
symptoms and diagnosis and seek means of obtaining early diagnosis.
METHOD
The retrospective study was carried out based on the analysis of the 
clinical records of all patients who were attended at the Department of 
Sanitary Dermatology of Acre, between 1998 and 2008. 
A collection of clinical pictures of patients was also accessed to 
evaluate evolution of the patients throughout treatment.
The data collected from each patient were: personal data; 
demographic data; history of the disease in relation to its manifestations 
and clinical evolution.
RESULTS AND DISCUSSION
Epidemiological data of Jorge Lobo’s disease in the state of Acre: 
There were 249 Jorge Lobo’s disease cases diagnosed in the Department 
of Dermatology of the Public Health Service between 1998 and 2008. 
Of these, 30 patients are females and 219 males. The average age at the 
time of diagnosis was 53 years, being the oldest patient 96 years-old 
and the youngest 14 years-old. The average time between the onset of 
symptoms and the time of diagnosis was 19 years; the longest time was 
60 years and the shortest one year. 
Early diagnosis of this disease is difficult. It could be observed that 
most patients sought health services only years after the onset of skin 
lesions, motivated either by increasing the size of the same, or by the 
appearance of new lesions. Among the patients studied in this work, 
the patient with the most recent onset of the disease presented an initial 
lesion, with evolution of one year in the lower lip, she was brought by 
her mother, who was already undergoing treatment. 
DIAS et al.9 noted that the majority of cases described in the literature 
are isolated cases, without reference to the disease in other family 
members. In patients studied in the present work, we report a father with 
extensive lesions throughout his body and his son with extensive lesions 
on the right arm. Also, the mother referred to above presented extensive 
lesions on the lower limbs and her daughter a single lesion on the lower 
Fig. 1 - Percentage of Jorge Lobo’s disease cases in the municipalities of Acre State. Insert: 
location of Acre State on North of Brazil. (State in red on West of the Brazilian map).
WOODS, W.J.; BELONE, A.F.F.; CARNEIRO, L.B. & ROSA, P.S. - Ten years experience with Jorge Lobo´s disease in the State of Acre, Amazon region, Brazil. Rev. Inst. Med. Trop. Sao 
Paulo, 52(5): 273-8, 2010.
275
lip. Since these four patients all lived in interior of the forest, there is no 
recorded evidence of transmission from one person to another, it is most 
likely that they became contaminated individually from an environmental 
source of the fungi.
LACAZ et al.11 indicate that no particular ethnic group has a greater 
susceptibility to acquire L. loboi and described the disease in white, blacks 
and Indians. However, the results of the present study show that there 
are very few Caucasians presenting Jorge Lobo’s disease in the state of 
the Acre, however, this could be a bias, because most of the population 
in Acre, with or without the disease, has dark skin. 
LACAZ et al.11 also reported that the disease affects mainly rubber 
cutters, miners, i. e., people who are in direct contact with the tropical 
forest. Similarly, all the patients in the present study worked or lived in 
the interior of the rain forest or on the banks of the rivers when the first 
symptoms appeared. Table 2 shows the distribution according to the 
municipality where the patients first appeared with symptoms of Jorge 
Lobo’s disease. There were no patients coming from the municipalities 
of Bujari, Assis Brasil, Jordan or Rodrigues Alves showing symptoms 
of the disease. Patients of the municipalities of Sena Madureira, Rio 
Branco, Xapuri, Plácido de Castro, Porto Acre and Epitaciolândia 
(municipalities with the highest numbers of cases), have easy access to 
the clinical center of the Dermatology Department in Rio Branco. Most 
of the other patients were seen when the medical doctor in the present 
work and his team traveled within these municipalities working with the 
Program for Elimination of Leprosy. We observed that among all patients 
who acquired the disease in the municipality of Sena Madureira, 14 of 
them lived on the banks of the Antimari River at the time, which is an 
endemic area for Jorge Lobo’s disease. Fig. 1 shows the distribution of 
Jorge Lobo’s Disease in the municipalities of the Acre, a state with a 
population of 691,169 inhabitants, with 4.5 inhabitants/km²-population 
density and altitude of 153 m above sea level in the capital, Rio Branco.
The river Purus and its tributaries pass through the municipalities 
of Sena Madureira, Manoel Urbano, Santa Rosa, Rio Branco, Xapuri, 
Brasiléia, Epitaciolândia and Boca do Acre in the state of Amazonas. 
Among the eight patients in the state of Amazonas, six are from Boca do 
Table 1 
Therapeutic results in Jorge Lobo’s disease
AUTHOR DRUGS USED RESULTS
REYES et al. 196022 Sulfadimetoxine 
1000 mg/day
Improvement of the infiltrations
SILVERIE et al., 196329 Sulfametoxipiridazine 500 mg/day Reduction of the nodules
LONDOÑO, 196814 Anfotericin B infiltration Unsatisfactory
BARUZZI & AZEVEDO, 19911 Clofazimine, 2 years
100 a 200 mg/day
Unsatisfactory
SILVA, 197826 Clofazimine 3 to 6 months 
200 mg/day
Slight reduction of lesions
TALHARI et al., 198132 Clofazimine 6 months to 3 years 
200 mg/day & electrocoagulation 
Decreased number of fungi
Some regression of lesions
CUCÊ et al., 19806 Ketaconazole 90 days 400 mg/day Decreased number of fungi
Some regression of lesions
BARUZZI et al., 19803 Ketaconazole 400 mg/day Moderate improvement
LAWRENCE & AJELLO, 198612 Ketaconazole 6 months 
200 mg/day
Unsatisfactory
OPROMOLLA, 199616 Itraconazole 6 months
100 to 200 mg/day
Unsatisfactory
PRADINAUD & TALHARI, 199621 Fluorcitosine, 50 days
100 mg/kg
Unsatisfactory
OPROMOLLA, 200018 Anfotericin B, DDS, Fluorcitosine Terbinafine and 
Clofazimine
Softening of the lesions
OPROMOLLA 200018 Clofazimine, DDS, 
Fluorcitosine and Itraconazole
Decreased viability
FISCHER et al., 200210 Itraconazole and Clofazimine
100 mg/kg
Clinical cure
ROSA et al. 200924 Itraconazole, Clofazimine, DDS
Surgical excision
Clinical cure
DDS = dapsone.
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Acre. This indicates that the Purus River and its tributaries, which include 
the river Antimari, are the largest endemic areas of Jorge Lobo’s disease 
in Acre. We believe that the valley of the river Juruá, a region that was 
not thoroughly studied, must have a hidden prevalence of the disease. 
Clinical aspects: Among the 249 patients in this study, 153 had 
localized lesions, 94 of them had lesions in one ear, of these 38 had lesions 
in the right ear and 56 in the left ear. None of the patients had lesions in 
both ears, but three patients had lesions in one ear and in another region of 
the body. This suggests multiple inoculation sites, as previously stated by 
OPROMOLLA et al.20. From the total number of cases, 55 had multifocal 
lesions and 41 had disseminated lesions (Fig. 2a, b, c, d).
Lesions were observed in the right upper limb in 34 patients and in 
the left in 36 patients. Seven patients had lesions on both upper limbs. In 
the lower limb, 20 patients had lesions on the right member and 34 on the 
left, four patients had lesions on both lower limbs and eight patients had 
lesions on the face. Another eight patients had lesions on the abdomen 
and six on the back. Two patients had lesions on the buttocks and one 
on the right (female) breast.
We draw attention to the fact that the left side of the body is the 
most affected. A possible explanation for this is that rubber cutters going 
through the forest carry the cutlass in his right hand and use their left hand 
or foot to push clear the bushes they have cut, making the left side more 
vulnerable to trauma through where fungi probably penetrate the skin.
Lesions may appear at any anatomic site, but there are no reports 
of lesions affecting the mucous membranes. Despite two patients with 
ulcerated lesions developing squamous cell carcinoma, the general 
health of the patient is good. The local symptom is intensive itching. 
When there are extensive lesions disseminated over a large area, beside 
the deformity they cause, the itching becomes unbearable. Ulceration is 
usually secondary to trauma because of itching.
Treatment of Jorge Lobo’s disease in Acre: Because of the lack of 
an effective medical treatment, in Acre, since 1979, patients have been 
submitted to surgeries to remove lesions, which improved substantially 
their quality of life. However, many of them presented recurrence of the 
symptoms after variable periods post surgery.
Over thirty years of experience working in the Leprosy Elimination 
Program of Acre, also following the guidelines of the distinguished Dr. 
Diltor OPROMOLLA18 (dapsone and clofazimine) and of the esteemed 
professor of Dermatology, Sinésio TALHARI et al.32 (clofazimine 200 
mg/6 months), the authors of the present work have used various forms 
of treatment for Jorge Lobo’s disease, all of them without very promising 
results17. 
From the total number of patients in Acre, 10 patients who had also 
been treated for leprosy demonstrated the best results of treatment. One 
of these patients, a female patient from the interior of the state finished 
her treatment for multibacillary leprosy, (rifampicin, clofazimine and 
dapsone), begged not to suspend the treatment because the Jorge Lobo’s 
disease lesions were softening and the itching was decreasing. During 
follow-up of the leprosy patients treated for multibacillary leprosy, who 
also had Jorge Lobo’s disease, we observed diminished itching caused by 
Jorge Lobo’s disease; the lesion showed mild atrophy and when the lesion 
was surgically removed, there was no recurrence. These patients were 
periodically examined, considering the clinical evolution and laboratorial 
Table 2 
Distribution of Jorge Lobo’s disease cases diagnosed in the State of Acre 
between 1998 and 2008, divided by municipality where patients lived when the 
first symptoms of the disease appeared
Municipality Number of cases
Sena Madureira 83
Rio Branco 33
Xapuri 28
Plácido de Castro 16
Porto Acre 15
Epitaciolandia 12
Tarauacá 11
Manoel Urbano 7
Cruzeiro do Sul 6
Senador Guiomar 5
Acrelandia 5
Brasileia 4
Capixaba 4
Mancio Lima 3
Porto Walter 2
Feijó 2
Santa Rosa 2
Marechal Taumaturgo 1
Amazonas State * 8
Rondonia State * 2
Total 249
* Treated in the Department of Dermatology in Rio Branco.
Fig. 2 - Characteristic clinical forms of Jorge Lobo’s disease. A. Isolated form; B. Multifocal 
form on lower limb; C. Extensive disseminated form; D. Ulcerated form on leg and foot. 
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examinations (biopsy and viability determination of the fungi collected 
from skin lesions) to document the improvement. 
 
CONCLUSION
The prevalence of Jorge Lobo’s disease in the state of Acre is not 
very high, 3.05/10,000 inhabitants, but the deformity and decreased 
productivity at work create a social burden for the carriers of this disease. 
We call attention to the fact that 96% of the patients are in the macro 
region of the valleys of the rivers Purus and Acre, where it is relatively 
easy to access the clinic of the Department of Sanitary Dermatology 
in Rio Branco. In the macro region of the river Juruá there is no health 
service available and there must be a hidden prevalence in this area. 
Nobody knows the true prevalence of this disease, which does not require 
compulsory notification. 
It was an interesting coincidence to find patients who have Jorge 
Lobo’s disease and are treated for multibacillary leprosy who showed 
great improvement of the lesions of Jorge Lobo’s disease, some no longer 
with viable fungi. Perhaps this treatment could be the starting point for 
further search for a cure for Jorge Lobo’s disease.
RESUMO
Dez anos de experiência com a Doença de Jorge Lobo no estado do 
Acre, região amazônica, Brasil
A doença de Jorge Lobo é micose cutânea e subcutânea que afeta 
pessoas na região Amazônica. O número de pacientes é relativamente 
pequeno, no entanto, a real prevalência da doença como problema de 
saúde pública é pouco conhecida. A doença de Jorge Lobo não é de 
notificação compulsória. Este estudo teve como objetivo determinar a 
prevalência, as áreas de ocorrência da doença de Jorge Lobo, além de 
sua evolução clínica. Um estudo retrospectivo foi desenvolvido com 
base na análise de prontuários de pacientes, incluindo documentação 
fotográfica dos mesmos, que foram atendidos no Departamento de 
Dermatologia Sanitária em Rio Branco e no interior do Estado. Foram 
registrados 249 casos em uma década em Rio Branco, 30 mulheres e 
219 homens. Do total 153 apresentavam lesões localizadas, 94 lesões 
em apenas uma orelha, 55 lesões multifocais e 41 lesões disseminadas. 
A média de tempo entre o início dos sintomas e o diagnóstico foi de 
19 anos. A média de idade no momento do diagnóstico foi de 53 anos, 
e as idades variaram de 14 a 96 anos.
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